A Cross Sectional Study of Expression of Cytokeratin 19 in Papillary Thyroid Carcinoma and Its Association with Prognostic Factors

Authors

  • Sneha Sheelwanth Tutor, Department of Pathology, Gulbarga Institute of Medical Sciences, Kalaburagi, Karnataka, India
  • Kirthi S Patil Tutor, Department of Pathology, Gulbarga Institute of Medical Sciences, Kalaburagi, Karnataka, India
  • Shivaraj S Hanchinal Senior Resident, Department of General Medicine, Mahavir Institute of Medical College, Vikarabad, India

Keywords:

Thyroid malignancies, endocrine malignancy, CK-19, CD56.

Abstract

Introduction: Thyroid malignancies are the most common endocrine malignancy. The most common malignancy in thyroid is papillary thyroid carcinoma. About 80% of all thyroid cancers are papillary carcinoma thyroid. Papillary carcinoma typically arises as an irregular, solid or cystic mass that comes from otherwise normal thyroid tissue. Papillary carcinoma has a high cure rate with 10-year survival rates for all patients with papillary carcinoma thyroid estimated at 80% to 90%.Materials and Methods: This cross-sectional study was conducted from January 2020 to December 2020. The cases included for the study were histopathologically proven cases of papillary thyroid carcinoma and its variants from thyroidectomy specimens received in Histopathology Department. Cases without proper data were excluded. It was a record-based study. Sample size =108. We took 160 samples for the study. Results: Of the total 160 cases of PTC, lymph node metastasis was noted in 38 cases that constituted 23.8 %, of which 2 cases was follicular variant of PTC and all others were classic variant of PTC. Out of 160 cases of PTC, 158 cases (98.8 %) showed 3+ or 4+ cytoplasmic and membranous positivity for CK19 and only 2 case showed a negative expression. 10 out of 24 cases of follicular variant showed a 3+ positivity, whereas columnar cell variant, tall cell variant and Warthin like variant showed 4+ positivity. Conclusion: Through this study it is concluded that, both CK-19 and CD56 can be used together as markers for PTC including all its variants but CK-19 cannot be used to assess the prognosis of papillary thyroid carcinoma as no association was identified in the study between the expression of CK-19 and prognostic factors.

Downloads

Published

2021-08-16

How to Cite

Sneha Sheelwanth, Kirthi S Patil, & Shivaraj S Hanchinal. (2021). A Cross Sectional Study of Expression of Cytokeratin 19 in Papillary Thyroid Carcinoma and Its Association with Prognostic Factors. International Journal of Health and Clinical Research, 4(14), 10–13. Retrieved from https://ijhcr.com/index.php/ijhcr/article/view/2216